EAACI Congress 2024
BackDermatology 1
Friday 31 May, 12:00 PM -
13:00 PM Valencia, Spain
Poster Zone
Thematic Poster Session
12:00
Acute Urticaria: Symptoms, Causes, and Evaluation of Phenotypes Prone to Chronicity
12:00
Children with cutaneous mastocytosis: a single center experiment
12:00
Efficacy of TAS5315, a Selective and Potent Bruton's Tyrosine Kinase Inhibitor, in Attenuating IgE-Mediated Biphasic Cutaneous Anaphylaxis in Transgenic Mice
12:00
Emulsion containing a new chitosan derivative versus petrolatum in children with mild atopic dermatitis: a randomised controlled trial
12:00
Features of chronic spontaneous urticaria in patients with atopic comorbidities: Results from CURE, the chronic urticaria registry
12:00
Frequent oil-baths and skin barrier during infancy in the PreventADALL study
12:00
Linguistic Adaptation of Urticaria Activity Score Over 7 Days (UAS7) to Latvian: Evaluating Disease Activity in Adult Patients with Chronic Spontaneous Urticaria in Latvia
12:00
Predicting Responses to Omalizumab in Antihistamine-Refractory Chronic Urticaria
12:00
Real world long-term data effectiveness of rupatadine in chronic urticaria: retrospective, monocentric, observational study
12:00
Safety of Remibrutinib in Patients With Chronic Spontaneous Urticaria: Results From the Phase 3 REMIX-1 and REMIX-2 Studies
12:00
Schnitzler syndrome: a case report
12:00
Severe Atopic Dermatitis and HyperEosinophilic Syndrome in Children Undergoing Dupilumab Treatment: Report of two cases
12:00
The PAF inhibitor Rupatadine has a positive influence on clinical and laboratory findings in patients with urticarial vasculitis
12:00
The UCARE Study on the Prevalence of Sleep Disorders and Nighttime Bruxism in People with Chronic Urticaria
